Trigeminal Neuralgia (Prosopalgia) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org

MarketOptimizer.org adds “Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014” to its store. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Market Research Reports

Market Optimizer - Market Research Reports

Dallas, Texas (PRWEB) August 24, 2014

Clinical trial report, “Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014″ provides data on the Trigeminal Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Trigeminal Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Trigeminal Neuralgia.

Trigeminal neuralgia (TN, or TGN), also known as prosopalgia, Fothergill's disease or formerly suicide disease is a neuropathic disorder characterized by episodes of intense pain in the face, originating from the trigeminal nerve. The clinical association between TN and hemifacial spasm is the so-called tic douloureux. It has been described as among the most painful conditions known to humankind. It is estimated that 1 in 15,000 or 20,000 people suffer from TN, although the actual figure may be significantly higher due to frequent misdiagnosis. In a majority of cases, TN symptoms begin appearing more frequently over the age of 50, although there have been cases with patients being as young as three years of age. It is more common in females than males. Trigeminal neuralgia was first described by physician John Fothergill and treated surgically by John Murray Carnochan both of whom were graduates of the University of Edinburgh Medical School.

Complete report details at http://www.marketoptimizer.org/trigeminal-neuralgia-global-clinical-trials-review-h2-2014.html .

Scope

  •     Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  •     Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  •     Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  •     Understand the dynamics of a particular indication in a condensed manner
  •     Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  •     Obtain discontinued trial listing for trials across the globe
  •     Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Order a purchase copy at http://www.marketoptimizer.org/contacts/purchase?rname=9639 .
(This is a premium report priced at US$2500 for a single user License and US $7500 for Corporate User License)

Major points in Table of Contents for This Report

Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Clinical Trials by G7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials

Top Companies Participating in Trigeminal Neuralgia Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Trigeminal Neuralgia
Jun 16, 2014: Convergence Pharmaceuticals’ Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study

Clinical Trial Profiles

Clinical Trial Overview of Top Companies
Merz Pharma GmbH & Co. KgaA
Desitin Arzneimittel GmbH
Convergence Pharmaceuticals Ltd.
Allodynic Therapeutics, LLC

Clinical Trial Overview of Top Institutes / Government
Stanford University
Thomas Jefferson University
University Health Network
National Institute of Dental and Craniofacial Research
Shahid Sadoughi University of Medical Sciences and Health Services
FDA Office of Orphan Products Development
University of Malaya
Riken Advanced Science Institute
University College London
Capital Medical University

Five Key Clinical Profiles

Explore more reports on Pharmaceuticals industry at http://www.marketoptimizer.org/category/energy-power/energy.

About Us:
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.


Contact

Follow us on: Contact's Google Plus